iBio, Inc. IBIO
Set alert
At close · Oct 30
After hours · Oct 30, 6:30 PM ET
- YTD
- -60.17%
- 1 year
- -50.41%
- Open
- 0.81
- Prev close
- 0.8136
- Mkt cap
- 38.19M
- Vol
- 214.29K
- Avg vol
- 707.20K
- EPS
- -0.32
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.74
- High
- 0.8106
- Forward P/E
- -1.44
- Beta
- 0.00
- Short ratio
- 1.92
- Inst. own
- 31.49%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 14, 2025
- 50-d avg
- 2.60
- 200-d avg
- 2.17
- 1y target
- 3.60
5D chart
Signals (152)
| Name | Time | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 1:50 PM | 2 days ago |
| RSI: Oversold | Oct 30, 1:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:30 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:25 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 11:45 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:15 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 11:15 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:30 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:25 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:45 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:35 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:35 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 3:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:15 PM | 3 days ago |
| RSI: Oversold | Oct 29, 12:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:15 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:00 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:00 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:15 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:10 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:35 PM | 4 days ago |
| RSI: Overbought | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:55 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:05 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:05 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:00 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:55 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:50 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:50 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:25 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:50 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:40 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:15 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:10 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:15 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:00 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:50 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:15 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:05 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:00 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:35 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:20 AM | 6 days ago |
News
3 days ago benzinga.com
Alpha Buying: 3 Beaten-Down Biotech Stocks Backed by a Specialist Investor
There are parts of the stock market where I am comfortable doing the research myself.Give me a community bank’s balance sheet, loan portfolio, and deposit information, and I can usually figure out…
1 week ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap…
-
2 weeks ago benzinga.com
iBio Highlights Preclinical Body-Composition Data From Obese NHP Study Evaluating IBIO-610, Activin E Antibody Candidate, Alone And In Combination With Semaglutide, GLP-1 Receptor Agonist Used To Treat Obesity
In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide aloneiBio expects to start first-in-human…
2 weeks ago globenewswire.com
iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610's Potential to Preserve Muscle in Combination with GLP-1 Therapy
In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide alone iBio expects to start first-in-human…
1 month ago defenseworld.net
Squarepoint Ops LLC Makes New Investment in iBio, Inc. $IBIO
Squarepoint Ops LLC acquired a new stake in iBio, Inc. (NASDAQ: IBIO) during the undefined quarter, according to its most recent disclosure with the SEC. The fund acquired 498,872 shares of the…
1 month ago benzinga.com
This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN rated Market Perform at $25.
-
1 month ago benzinga.com
HC Wainwright & Co. Initiates Coverage On iBio with Buy Rating, Announces Price Target of $7
HC Wainwright & Co. analyst Ananda Ghosh initiates coverage on iBio (NASDAQ:IBIO) with a Buy rating and announces Price Target of $7.
-
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after-market session. The company's market cap stands at $50.2 million. Eocene (NASDAQ:EOCN) shares rose…
2 months ago globenewswire.com
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and…
2 months ago globenewswire.com
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and…
2 months ago globenewswire.com
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary…
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Gossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market session. The company's market cap stands at $66.4 million. ProMIS Neurosciences (NASDAQ:PMN) shares…
-
4 months ago benzinga.com
iBio Announces New Preclinical Data From Obese Non-Human Primate Study Evaluating IBIO-610, Activin E Antibody Candidate
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approachWhen combined with semaglutide, IBIO-610 drove…
4 months ago globenewswire.com
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach
-
4 months ago benzinga.com
Raymond James Initiates Coverage On iBio with Outperform Rating, Announces Price Target of $5
Raymond James analyst Martin Auster initiates coverage on iBio (NASDAQ:IBIO) with a Outperform rating and announces Price Target of $5.
5 months ago globenewswire.com
iBio to Participate in Upcoming Healthcare Investor Conferences
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or the “Company”), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary…
-
5 months ago benzinga.com
iBio Begins Human Testing of Obesity Drug Candidate, First Patient Dosed in Company's Initial Clinical Trial
iBio, Inc. (NASDAQ:IBIO) ("iBio" or the "Company"), a clinical-stage AI-driven innovator developing therapies for cardiometabolic and cardiopulmonary diseases and obesity, today announced the dosing…
5 months ago globenewswire.com
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition
-
5 months ago benzinga.com
iBio Q3 EPS $(0.07) Misses $(0.06) Estimate
iBio (AMEX:IBIO) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 85.71 percent increase over losses of $(0.49) per…
5 months ago globenewswire.com
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
Received regulatory clearance to initiate its Phase 1 clinical trial of IBIO-600 in Australia Announced a strategic pipeline expansion into pulmonary hypertension associated with heart failure with…
6 months ago globenewswire.com
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First participants expected to be dosed in 2Q 2026 SAN…
7 months ago seekingalpha.com
iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypertension in Heart Failure Transcript
iBio, Inc. (IBIO) Discusses Bispecific Antibody Program and Rationale for Targeting Pulmonary Hypertension in Heart Failure Transcript
-
7 months ago benzinga.com
iBio, Inc. To Host Call On PH-HFpEF Pipeline Expansion, Targets Bispecific Antibody Candidate Selection In Q3 2026
iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced the Company will host a conference call on Tuesday,…
7 months ago globenewswire.com
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET
-
7 months ago benzinga.com
iBio Reports Early Study Results Showing Experimental Obesity Drug Reduced Fat in Animals
iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced new preclinical data from its obese non-human primate…
7 months ago globenewswire.com
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
Study demonstrated reduction of 6.7% visceral fat and 5.2% total fat mass in obese non-human primates (NHPs) despite high-calorie diet Study demonstrated reduction of 6.7% visceral fat and 5.2% total…
-
8 months ago benzinga.com
Jones Trading Initiates Coverage On iBio with Buy Rating, Announces Price Target of $7
Jones Trading analyst Catherine Novack initiates coverage on iBio (NASDAQ:IBIO) with a Buy rating and announces Price Target of $7.
8 months ago defenseworld.net
iBio (NASDAQ:IBIO) versus Gemini Therapeutics (NASDAQ:GMTX) Critical Review
iBio (NASDAQ: IBIO - Get Free Report) and Gemini Therapeutics (NASDAQ: GMTX - Get Free Report) are both manufacturing companies, but which is the superior stock? We will contrast the two companies…
-
8 months ago benzinga.com
iBio Enters $100M At-The-Market Offering Agreement With Jefferies LLC; Terminates Prior $7.35M ATM Program
On February 27, 2026, iBio, Inc., a Delaware corporation (the "Company"), entered into an Open Market Sale AgreementSM (the "ATM Agreement") with Jefferies LLC ("Jefferies") providing for the sale by…
-
8 months ago benzinga.com
iBio Files Preliminary Prospectus To Issue Up To $200M In Securities
The information contained in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is…
8 months ago globenewswire.com
iBio to Participate in Upcoming Investor Conferences
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive…
8 months ago defenseworld.net
Critical Review: iBio (NYSE:IBIO) versus Vaxxinity (NASDAQ:VAXX)
Vaxxinity (NASDAQ: VAXX - Get Free Report) and iBio (NYSE: IBIO - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on…
-
8 months ago benzinga.com
iBio Q2 EPS $(0.09) Misses $(0.07) Estimate
iBio (AMEX:IBIO) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 81.25 percent increase over losses of $(0.48) per…
8 months ago globenewswire.com
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway
9 months ago zacks.com
iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
iBio (IBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-
9 months ago benzinga.com
iBio Files Prospectus For Resale Of 11,061,738 Shares Of Common Stock By Selling Stockholders
11,061,738 Shares of Common StockThis prospectus relates to the resale from time to time of up to 11,061,738 shares of common stock, par value $0.001 per share (the "Common Stock") of iBio, Inc. (the…
9 months ago defenseworld.net
Contrasting Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO)
Vincerx Pharma (NASDAQ: VINC - Get Free Report) and iBio (NYSE: IBIO - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses…
9 months ago defenseworld.net
iBio (NYSEMKT:IBIO) Trading 8.3% Higher – Here’s Why
Shares of iBio, Inc. (NYSEMKT:IBIO - Get Free Report) traded up 8.3% during trading on Friday. The stock traded as high as $2.35 and last traded at $2.35. 1,928,910 shares were traded during trading,…
-
9 months ago benzinga.com
iBio Announces Private Placement Of Approximately $26M
The financing was led by Frazier Life Sciences and included participation from other existing investors.iBio intends to use the net proceeds received from the offering to advance its preclinical…
9 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
11 months ago benzinga.com
iBio Q1 EPS $(0.11) Misses $(0.10) Estimate, Sales $100.000K Beat $25.000K Estimate
iBio (AMEX:IBIO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 7.84 percent. This is a 76.09 percent increase over losses of $(0.46) per…
-
1 year ago benzinga.com
iBio Announces New Preclinical Data From Obese NHP Study Evaluating IBIO-610, Activin E Antibody Candidate Supported By Preclinical Data
Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain following GLP-1 treatment…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
1 year ago benzinga.com
Why Did iBio Shares Surge Over 11% In Pre-Market Trading?
iBio shares rose sharply after announcing upcoming presentations on its obesity treatment candidate at two industry conferences.